Form DEFA14A Spyre Therapeutics, Inc.

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. ACN
2. SPCX
3. NVDA
4. MSTR
5. MU
6. DFTX
7. BAUFF
8. ICE
9. KR
10. RGA

Go back to Form DEFA14A Spyre Therapeutics, Inc.

Leerink on Spyre (SYRE): 'one of our Top Picks for 2026'

April 13, 2026 8:21 AM EDT

Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).

The analyst comments "SYRE (OP) announced positive topline results from the open-label SPY001 (anti-47) monotherapy cohort of the Phase 2 SKYLINE platform trial in ulcerative colitis (UC). Importantly, SPY001 demonstrated class-leading efficacy on the study's primary and key secondary endpoints, showing an impressive -9.2pt reduction from baseline on the primary RHI endpoint and a 40% clinical remission rate at week 12 - both data points suggesting differentiated efficacy relative to TAK's (NR)... More

Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'

April 13, 2026 7:46 AM EDT

Guggenheim analyst Yatin Suneja reiterated a Buy rating and $115.00 price target on Spyre (NASDAQ: SYRE).

The analyst comments "Spyre announced topline results for SPY001's monotherapy study in SKYLINE-UC Part A (n~130). Across multiple endpoints (RHI from baseline, clinical remission, endoscopic improvement), SPY001/47 consistently outperformed TAK's Entyvio (both Week 6 & 14 comps), with most notable efficacy outcome of 40% clinical remission at week 12 (Fig 1 & 2). The induction CR data is one of the highest we have seen and significantly... More